[go: up one dir, main page]

MX2009013449A - Potenciacion de quimioterapia de cancer. - Google Patents

Potenciacion de quimioterapia de cancer.

Info

Publication number
MX2009013449A
MX2009013449A MX2009013449A MX2009013449A MX2009013449A MX 2009013449 A MX2009013449 A MX 2009013449A MX 2009013449 A MX2009013449 A MX 2009013449A MX 2009013449 A MX2009013449 A MX 2009013449A MX 2009013449 A MX2009013449 A MX 2009013449A
Authority
MX
Mexico
Prior art keywords
imidazo
dioxo
piperidinyl
tetrahydro
dihydro
Prior art date
Application number
MX2009013449A
Other languages
English (en)
Inventor
Aktham Aburub
Marcio Chedid
Venkatraghavan Vasudevan
Thomas Albert Engler
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39737054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009013449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2009013449A publication Critical patent/MX2009013449A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un método mejorado para tratar cáncer gástrico, cáncer de ovario, cáncer de pulmón de células no pequeñas, o cáncer colorectal en un paciente, así como también composiciones farmacéuticas empleadas por el método y un proceso para preparar dichas composiciones.
MX2009013449A 2007-07-02 2008-06-20 Potenciacion de quimioterapia de cancer. MX2009013449A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94751207P 2007-07-02 2007-07-02
PCT/US2008/067614 WO2009006043A2 (en) 2007-07-02 2008-06-20 Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepine

Publications (1)

Publication Number Publication Date
MX2009013449A true MX2009013449A (es) 2010-01-15

Family

ID=39737054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013449A MX2009013449A (es) 2007-07-02 2008-06-20 Potenciacion de quimioterapia de cancer.

Country Status (22)

Country Link
US (2) US8318713B2 (es)
EP (1) EP2173348B1 (es)
JP (2) JP5551589B2 (es)
KR (1) KR101230085B1 (es)
CN (2) CN101743005B (es)
AR (1) AR067112A1 (es)
AU (1) AU2008270732B2 (es)
BR (1) BRPI0813789A2 (es)
CA (1) CA2691587C (es)
CL (2) CL2008001848A1 (es)
EA (2) EA018447B1 (es)
ES (1) ES2561202T3 (es)
IL (2) IL202237A (es)
MA (1) MA31677B1 (es)
MX (1) MX2009013449A (es)
MY (1) MY154472A (es)
NZ (1) NZ581355A (es)
PE (1) PE20090838A1 (es)
TW (1) TWI428132B (es)
UA (1) UA97400C2 (es)
WO (1) WO2009006043A2 (es)
ZA (1) ZA200908725B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
SG175207A1 (en) 2009-04-14 2011-11-28 Lilly Co Eli Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
US20150017245A1 (en) * 2011-09-22 2015-01-15 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
WO2016175324A1 (ja) * 2015-04-30 2016-11-03 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
US10213511B2 (en) * 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10016507B2 (en) * 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
US20240293425A1 (en) * 2021-06-03 2024-09-05 University Of Cincinnati Bzd-1 as a chemosensitizer of cancer
CN113956157B (zh) * 2021-11-18 2024-05-03 西安都创医药科技有限公司 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP1788086A1 (en) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Death Domain Containing Receptor 5
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP4414232B2 (ja) * 2002-03-05 2010-02-10 イーライ リリー アンド カンパニー キナーゼ阻害物質
KR20050052500A (ko) * 2002-09-19 2005-06-02 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 이미다조피리딘
JP5033624B2 (ja) 2004-07-09 2012-09-26 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ＧＳＫ−３βの変更および増殖性疾患の治療方法
GB0418328D0 (en) * 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
JP2008541701A (ja) * 2005-05-04 2008-11-27 ユニヴァーシティ オブ サウス フロリダ がんの対象における処置応答の予測
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化

Also Published As

Publication number Publication date
AR067112A1 (es) 2009-09-30
KR20100017984A (ko) 2010-02-16
TW200911272A (en) 2009-03-16
JP5551589B2 (ja) 2014-07-16
JP2014114297A (ja) 2014-06-26
ES2561202T3 (es) 2016-02-25
MA31677B1 (fr) 2010-09-01
HK1141236A1 (zh) 2010-11-05
CL2008001848A1 (es) 2009-05-29
CN102772416A (zh) 2012-11-14
ZA200908725B (en) 2011-02-23
CL2011003046A1 (es) 2012-08-24
EA023697B1 (ru) 2016-07-29
KR101230085B1 (ko) 2013-02-05
IL218443A0 (en) 2012-04-30
EA018447B1 (ru) 2013-08-30
AU2008270732A1 (en) 2009-01-08
UA97400C2 (uk) 2012-02-10
US8648063B2 (en) 2014-02-11
BRPI0813789A2 (pt) 2014-12-30
US8318713B2 (en) 2012-11-27
EP2173348A2 (en) 2010-04-14
MY154472A (en) 2015-06-30
IL202237A0 (en) 2010-06-16
EA201201155A1 (ru) 2014-11-28
JP2010532364A (ja) 2010-10-07
NZ581355A (en) 2012-04-27
IL202237A (en) 2014-05-28
CN101743005A (zh) 2010-06-16
US20100166884A1 (en) 2010-07-01
US20130039996A1 (en) 2013-02-14
CN101743005B (zh) 2013-06-12
CA2691587A1 (en) 2009-01-08
EA201070085A1 (ru) 2010-04-30
WO2009006043A2 (en) 2009-01-08
PE20090838A1 (es) 2009-07-02
WO2009006043A3 (en) 2009-04-16
TWI428132B (zh) 2014-03-01
EP2173348B1 (en) 2015-12-09
AU2008270732B2 (en) 2013-01-31
CA2691587C (en) 2013-09-24

Similar Documents

Publication Publication Date Title
MX2009013449A (es) Potenciacion de quimioterapia de cancer.
NZ711948A (en) Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
WO2012065085A4 (en) Methods of treating cancer
IL201691A0 (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl)-3h- imidazo [4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
EP3130585A3 (en) Pyrrolo[3,2-d]pyrimidine-4-amine derivatives and related compounds for the treatment of cancer
JP2010532364A5 (es)
SG170033A1 (en) Octahydro-pyrrolo[3,4-b] pyrrole derivatives and their use as histamine-3 receptor ligands
WO2009087225A3 (en) Pyrrolopyrimidines and pyrrolopyridines
TN2010000167A1 (en) Organic compounds
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
WO2009063970A1 (ja) 抗gpr49抗体を用いる癌の診断および治療
IL212716A0 (en) Thieno [3,2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer
GEP20115231B (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
MX2011008452A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
WO2007092646A3 (en) Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EA201490472A1 (ru) Комбинированная терапия рака hsp90-ингибитором и антиметаболитом
WO2010028187A3 (en) Methods and compositions for the treatment of cancer
NZ594186A (en) Indole derivatives as anticancer agents
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
SI1869038T1 (sl) Substituirane 5,6,7,8-tetrahidro-imidazo(1,2-a)piridin-2-ilaminske spojine in njihova uporaba za pripravo zdravil
WO2006081445A3 (en) Treatment of metastasized tumors
TW200730530A (en) Lyophilized compositions of a triazolopyrimidine compound

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration